List of Intrarosa drug patents

Intrarosa is owned by Millicent.

Intrarosa contains Prasterone.

Intrarosa has a total of 3 drug patents out of which 0 drug patents have expired.

Intrarosa was authorised for market use on 16 November, 2016.

Intrarosa is available in insert;vaginal dosage forms.

Intrarosa can be used as intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

The generics of Intrarosa are possible to be released after 19 March, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629129 MILLICENT Pharmaceutical compositions
Aug, 2028

(5 years from now)

US8957054 MILLICENT Pharmaceutical compositions
Jan, 2030

(6 years from now)

US8268806 MILLICENT Pharmaceutical compositions
Mar, 2031

(8 years from now)

Drugs and Companies using PRASTERONE ingredient

Market Authorisation Date: 16 November, 2016

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Dosage: INSERT;VAGINAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in